Rebeca Martín, David Rios-Covian, Eugénie Huillet, Sandrine Auger, Sara Khazal, Luis G Bermúdez-Humarán, Harry Sokol, Jean-Marc Chatel, Philippe Langella
{"title":"Faecalibacterium: a bacterial genus with promising human health applications.","authors":"Rebeca Martín, David Rios-Covian, Eugénie Huillet, Sandrine Auger, Sara Khazal, Luis G Bermúdez-Humarán, Harry Sokol, Jean-Marc Chatel, Philippe Langella","doi":"10.1093/femsre/fuad039","DOIUrl":null,"url":null,"abstract":"<p><p>In humans, many diseases are associated with alterations in gut microbiota, namely increases or decreases in the abundance of specific bacterial groups. One example is the genus Faecalibacterium. Numerous studies have underscored that low levels of Faecalibacterium are correlated with inflammatory conditions, with inflammatory bowel disease (IBD) in the forefront. Its representation is also diminished in the case of several diseases, including colorectal cancer (CRC), dermatitis, and depression. Additionally, the relative presence of this genus is considered to reflect, at least in part, intestinal health status because Faecalibacterium is frequently present at reduced levels in individuals with gastrointestinal diseases or disorders. In this review, we first thoroughly describe updates to the taxonomy of Faecalibacterium, which has transformed a single-species taxon to a multispecies taxon over the last decade. We then explore the links discovered between Faecalibacterium abundance and various diseases since the first IBD-focused studies were published. Next, we examine current available strategies for modulating Faecalibacterium levels in the gut. Finally, we summarize the mechanisms underlying the beneficial effects that have been attributed to this genus. Together, epidemiological and experimental data strongly support the use of Faecalibacterium as a next-generation probiotic (NGP) or live biotherapeutic product (LBP).</p>","PeriodicalId":12201,"journal":{"name":"FEMS microbiology reviews","volume":"47 4","pages":""},"PeriodicalIF":10.1000,"publicationDate":"2023-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/6f/fuad039.PMC10410495.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FEMS microbiology reviews","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/femsre/fuad039","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 6
Abstract
In humans, many diseases are associated with alterations in gut microbiota, namely increases or decreases in the abundance of specific bacterial groups. One example is the genus Faecalibacterium. Numerous studies have underscored that low levels of Faecalibacterium are correlated with inflammatory conditions, with inflammatory bowel disease (IBD) in the forefront. Its representation is also diminished in the case of several diseases, including colorectal cancer (CRC), dermatitis, and depression. Additionally, the relative presence of this genus is considered to reflect, at least in part, intestinal health status because Faecalibacterium is frequently present at reduced levels in individuals with gastrointestinal diseases or disorders. In this review, we first thoroughly describe updates to the taxonomy of Faecalibacterium, which has transformed a single-species taxon to a multispecies taxon over the last decade. We then explore the links discovered between Faecalibacterium abundance and various diseases since the first IBD-focused studies were published. Next, we examine current available strategies for modulating Faecalibacterium levels in the gut. Finally, we summarize the mechanisms underlying the beneficial effects that have been attributed to this genus. Together, epidemiological and experimental data strongly support the use of Faecalibacterium as a next-generation probiotic (NGP) or live biotherapeutic product (LBP).
期刊介绍:
Title: FEMS Microbiology Reviews
Journal Focus:
Publishes reviews covering all aspects of microbiology not recently surveyed
Reviews topics of current interest
Provides comprehensive, critical, and authoritative coverage
Offers new perspectives and critical, detailed discussions of significant trends
May contain speculative and selective elements
Aimed at both specialists and general readers
Reviews should be framed within the context of general microbiology and biology
Submission Criteria:
Manuscripts should not be unevaluated compilations of literature
Lectures delivered at symposia must review the related field to be acceptable